Open surgical bypass is the gold standard, but endovascular therapies may provide value for high-risk patients with long femoropopliteal lesions.

The interventional treatment of tricuspid valve disease has evolved in recent years thanks to new research and critical FDA approvals. Cardiologist Ryan Kaple, MD, reviewed this trend for a new video interview.

ADP offers care teams multiple benefits not seen with traditional wire-based physiologic assessments. A roundtable of 17 expert clinicians discussed the topic at length, and their findings were used to develop a new manuscript published in JSCAI.

There is a risk of users making adjustments during treatment that are unnecessary. The FDA is still evaluating the issue at this time.

Medtronic has held a minority investment in CathWorks for several years, and the two organizations entered into a co-promotion agreement in 2022. Once finalized, the move will increase Medtronic's presence in the cath lab. 

The Amend device from Valcare Medical has a closed ring shape similar to the annuloplasty rings used to treat MR during open-heart surgeries. These early patients will be followed for a total of five years.

Researchers explored data from more than 1,000 patients with calcified coronary artery disease who required plaque modification. IVL and atherectomy were linked to comparable success rates, but adverse events were less likely with IVL.

The new certification is focused on the importance of high-quality care and real-world patient outcomes. It will be based on the same data care teams already submit if they participate in the STS Adult Cardiac Surgery Database, ACC CathPCI Registry or STS/ACC TVT Registry.